Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.051
Neutral
RSI(14)
43.682
Neutral
STOCH(KDJ)(9,3,3)
64.411
Neutral
ATR(14)
0.147
Low Volatility
CCI(14)
1.596
Neutral
Williams %R
53.684
Neutral
TRIX(12,20)
-0.324
Sell
StochRSI(14)
14.258
Sell
Search
Valneva SE
VALNAdd to Watchlist
4.970USD
-0.120-2.36%
Close 07-31 16:00（ET）Quotes delayed by 15 min
469.87MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.36%
5 Days
+3.97%
1 Month
-4.88%
6 Months
-45.68%
Year to Date
-43.65%
1 Year
-31.15%
Key Figures
5.090Open
5.090High
23.01KVolume
LossP/E TTM
6.09P/E Dynamic
--Dividend TTM
0.03%Turnover Ratio
5.086Prev. Close
4.920Low
98.76KTurnover
LossP/E Static
4.79P/B
0.00%Div Yield TTM
-32.32%ROA
12.25052wk High
2.09Volume Ratio
-12.25MNet Profit
86.88MShares
-1.3936EPS TTM
1.75Beta
-109.57%ROE
5.06052wk Low
3.34%Amplitude
15.29%Gross Margin
469.87MMarket Cap
-2.46Reward/Risk
2.36%Risk Rate
TradingKey Stock Score of Valneva SE
Currency: USD Updated: 2026-07-31Key Insights
Valneva SE's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 130 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.20.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Valneva SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Valneva SE Highlights
StrengthsRisks
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 33.76% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 205.61M.
Overvalued
The company’s latest PE is -3.57, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.21M shares, decreasing 5.60% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 14.79 shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
12.200
Target Price
+145.47%
Upside Space
Valneva SE News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
4
analysts
Buy
Current Rating
12.200
Target Price
+145.47%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Valneva SE
VALN
4
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
5.029
Sell
MA10
4.938
Buy
MA20
5.063
Sell
MA50
5.347
Sell
MA100
6.053
Sell
MA200
7.773
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Valneva SE Info
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Ticker SymbolVALN
CompanyValneva SE
CEOLingelbach (Thomas)
Websitehttps://valneva.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52827.700
+449.700 (+0.86%)
28446.700
+285.800 (+1.01%)
7528.400
+53.300 (+0.71%)
14609.000
-140.000 (-0.95%)
63363.000
+511.000 (+0.81%)
6416.200
+50.800 (+0.80%)
79.430
-6.504 (-7.57%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4060.230
+18.800 (+0.47%)
FAQs
What is the current price of Valneva SE (VALN)?
The current price of Valneva SE (VALN) is 4.97.
What is the symbol of Valneva SE?
The ticker symbol of Valneva SE is VALN.
What is the 52-week high of Valneva SE?
The 52-week high of Valneva SE is 12.25.
What is the 52-week low of Valneva SE?
The 52-week low of Valneva SE is 5.06.
What is the market capitalization of Valneva SE?
The market capitalization of Valneva SE is 469.87M.
Is Valneva SE (VALN) currently rated as Buy, Hold, or Sell?
According to analysts, Valneva SE (VALN) has an overall rating of Buy, with a price target of 12.20.
What is the Earnings Per Share (EPS TTM) of Valneva SE (VALN)?
The Earnings Per Share (EPS TTM) of Valneva SE (VALN) is -1.61.